By Sherri
Oslick —

About
Court
Report:  Each week we will report briefly on recently filed
biotech and pharma cases.

Allergan Inc. et al. v. Paddock Laboratories Inc.
1:10-cv-00501; filed June 9, 2010 in the District
Court of Delaware

• Plaintiffs:  Allergan Inc.; Allergan USA Inc.;
Allergan Sales LLC; Endo Pharmaceuticals Solutions Inc.; Supernus
Pharmaceuticals Inc. 
• Defendant:  Paddock Laboratories Inc.

Infringement of U.S. Patent No. 7,410,978 ("Once
Daily Dosage Forms of Trospium," issued August 12, 2008) following a
Paragraph IV certification as part of Paddock's filing of an ANDA to
manufacture a generic version of Allergan's Sanctura XR® (trospium, used to
treat overactive bladder).  View
the complaint here.

Bayer Schering Pharma AG et al. v. Teva Pharmaceutical
Industries Ltd. et al.
2:10-cv-00872; filed June 7, 2010 in the District
Court of Nevada

• Plaintiffs:  Bayer Schering Pharma AG; Bayer
Healthcare Pharmaceuticals Inc.
• Defendants:  Teva Pharmaceutical Industries Ltd.;
Teva Pharmaceuticals USA, Inc.; Barr Pharmaceuticals LLC; Barr Laboratories,
Inc.

Infringement of U.S. Patent Nos. RE37,564 ("Composition
for Contraception," issued February 26, 2002), RE37,838 (same title,
issued September 10, 2002), and RE37,253 (same title, issued September 16, 2003)
following a Paragraph IV certification as part of defendants' filing of an ANDA
to manufacture a generic version of Bayer's Yaz® (drospirenone & ethinyl
estradiol, used for oral contraception).  View the complaint here.

Abbott Laboratories et al. v. Sun Pharmaceutical Industries
Ltd. et al.
1:10-cv-00488; filed June 4, 2010 in the District
Court of Delaware

• Plaintiffs:  Abbott Laboratories; Abbott
Respiratory LLC
• Defendants:  Sun Pharmaceutical Industries Ltd.;
Sun Pharma Global FZE

Infringement of U.S. Patent Nos. 6,080,428 ("Nicotinic
Acid Compositions for Treating Hyperlipidemia and Related Methods Therefor,"
issued June 27, 2000) and 6,469,035 ("Methods of Pretreating
Hyperlipidemic Individuals with a Flush Inhibiting Agent Prior to the Start of
Single Daily Dose Nicotinic Acid Therapy to Reduce Flushing Provoked by
Nicotinic Acid," issued October 22, 2002) following a Paragraph IV
certification as part of Sun's filing of an ANDA to manufacture a generic
version of Abbott's Niaspan® (niacin extended-release tablets, used to treat
hypercholesterolemia).  View the
complaint here.

Otsuka Pharmaceutical Co., Ltd. v. Zydus Pharmaceuticals USA, Inc.
et al.
3:10-cv-02857; filed June 4, 2010 in the District
Court of New Jersey

• Plaintiff:  Otsuka Pharmaceutical Co., Ltd.
• Defendants:  Zydus Pharmaceuticals USA, Inc.;
Cadila Healthcare Ltd.

Infringement of U.S. Patent No. 5,006,528 ("Carbostyril
Derivatives," issued April 9, 1991) following a Paragraph IV certification
as part of Zydus' filing of an ANDA to manufacture a generic version of Otsuka's
Abilify® (aripiprazole, used to treat bipolar disorder and schizophrenia).  View the complaint here.

Abbott Laboratories et al. v. Ranbaxy Laboratories Ltd. et al.
2:10-cv-02869; filed June 4, 2010 in the District
Court of New Jersey

• Plaintiffs:  Abbott Laboratories; Laboratoires
Fournier S.A.
• Defendants:  Ranbaxy Laboratories Ltd.; Ranbaxy
Pharmaceuticals, Inc.; Ranbaxy Inc.

Infringement of U.S. Patent Nos. 6,277,405 ("Fenofibrate
Pharmaceutical Composition Having High Bioavailability and Method for Preparing
It," issued August 21, 2001), 7,037,529 (same title, issued May 2, 2006),
and 7,041,319 ("Fenofibrate Pharmaceutical Composition Having High
Bioavailabilty," issued May 9, 2006) following a Paragraph IV
certification as part of Ranbaxy's filing of an ANDA to manufacture a generic
version of Abbott's Tricor® (fenofibrate, used in the treatment of increased
triglyceride levels).  View the
complaint here.

Elan Pharma International Ltd. et al. v. Ranbaxy Laboratories
Ltd. et al.
2:10-cv-02872; filed June 4, 2010 in the District
Court of New Jersey

• Plaintiffs:  Elan Pharma International Ltd.;
Fournier Laboratories Ireland Ltd.
• Defendants:  Ranbaxy Laboratories Ltd.; Ranbaxy
Pharmaceuticals, Inc.; Ranbaxy Inc.

Infringement of U.S. Patent Nos. 7,276,249 ("Nanoparticulate
Fibrate Formulations," issued October 2, 2007) and 7,320,802 ("Methods
of Treatment Using Nanoparticulate Fenofibrate Compositions," issued
January 22, 2008), all licensed to Abbott, following a Paragraph IV
certification as part of Ranbaxy's filing of an ANDA to manufacture a generic
version of Abbott's Tricor® (fenofibrate, used in the treatment of increased
triglyceride levels).  View the
complaint here.